삼성서울병원

Ko En

Kim, Won Seog M.D

TITLE
Professor of Hematology and Oncology, Sungkyunkwan University School of Medicine
Treament Schedule 12 月
DATE
SUN
01
MON
02
TUE
03
WEB
04
THU
05
FRI
06
SAT
07
SUN
08
MON
09
TUE
10
WEB
11
THU
12
FRI
13
SAT
14
SUN
15
MON
16
TUE
17
WEB
18
THU
19
FRI
20
SAT
21
SUN
22
MON
23
TUE
24
WEB
25
THU
26
FRI
27
SAT
28
SUN
29
MON
30
TUE
31
AM
PM
Treament Schedule 01 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical School

Seoul National University College of Medicine

Specialty Training

Fellowship   Seoul National University Hospital
Samsugn Medical Center
Residency   Seoul National University Hospital
Internship   Seoul National University Hospital

Other Education

Post Doc Fellow: NHLBI. NIH USA

Clinical & Research Interests

Malignant Lymphoma

Selected Publications

  • Leuk Lymphoma. 2017 Jun;58(6):1341-1348. doi: 10.1080/10428194.2016.1236380. Epub 2016 Oct 9. Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma Moon SH11, Lee AY1, Kim WS2, Kim SJ2, Cho YS1, Choe YS1, Kim BT1, Lee KH1.
    View PubMed
  • Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25. Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.
    View PubMed
  • Oncotarget. 2017 Mar 7;8(10):17038-17049. doi: 10.18632/oncotarget.14928. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP Jung H11,2, Yoo HY3, Lee SH3, Shin S4, Kim SC1, Lee S1, Joung JG1, Nam JY1,3, Ryu D1,3, Yun JW1,5, Choi JK2, Ghosh A5, Kim KK5, Kim SJ6, Kim WS6, Park WY1, Ko YH4.
    View PubMed
  • Oncotarget. 2017 Mar 28;8(13):22014-22022. doi: 10.18632/oncotarget.15782. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm Yoon N11, Ahn S2, Yong Yoo H3, Jin Kim S4, Seog Kim W4, Hyeh Ko Y5.
    View PubMed
  • Oncotarget. 2017 Feb 21;8(8):13782-13791. doi: 10.18632/oncotarget.14636. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP Hong JY11, Ryu KJ2, Park C3, Hong M4, Ko YH5, Kim WS6, Kim SJ2,6.
    View PubMed